Congratulations to Cedar Park’s very on ExoDiscovery Technologies Inc.!

Company Innovation 

The Oversight Committee approved a $4 million Texas Device and Diagnostics Company Award for ExoDiscovery | Revolutionary Cancer Detection & Monitoring Technology a Cedar Park company developing a new blood test for non-small cell lung cancer (NSCLC), the most common form of lung cancer. Because NSCLC grows slowly, early detection is critical to improving patient outcomes.  ExoDiscovery’s test analyzes cancer signals inside tiny particles in the blood called exosomes and delivers results within a day—far faster than the two-week turnaround common with standard diagnostic tests. This faster, simpler process could move patients into treatment sooner.